Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00397345 | TroVax Renal Immunotherapy Survival Trial | PHASE3 | COMPLETED | 733 | — | — | Sep 1, 2006 | Dec 1, 2009 | Oct 19, 2020 | 152 | United States, France +8 |
| Arm | Type | Description |
|---|---|---|
| Trovax | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Trovax | BIOLOGICAL | 1ml IM injection 2-8 weeks apart. |
| Placebo | BIOLOGICAL | Placebo |
| Standard of care therapy | BIOLOGICAL | subcutaneous low dose IL-2, interferon-α or sunitinib |
Inclusion Criteria: * Signed informed consent. The patient must be competent to give written informed consent and comply with the protocol requirements. * Locally advanced or metastatic, histologically proven clear cell renal carcinoma. * Primary tumour surgically removed (some residual advanced pr...